This protocol is currently under development, but is based on the success of Professor Pfeifer’s Prostate Protocol (see separate entry). Preliminary studies are positive, and the protocol focuses on nutritional support to boost the immune system and protect against cancer. The protocol includes BioBran, Indol-3-Carbinol and Immusan.

Pfeifer’s Breast Protocol is a treatment consisting of natural supplements which include Indol-3-Carbinol, Biobran and Immusan. Indol-3-Carbinol (I-3-C) is found in cruciferous vegetables such as cabbage, Brussels sprouts, broccoli and bok choy. When treating breast cancer, large amounts of I-3-C are required, so it is extracted. In experimental, pre-clinical studies in animals and humans, it has been shown that I-3-C and its metabolites possess anti-carcinogenic effects.

It helps reduce blood concentration of oestrogen metabolite associated with breast and endometrial cancer, and reduces growth rate of cancer cells. Daily supplements of 400-600 mg. MGN-3 (Biobran) is a natural food preparation derived from pre-digested rice bran which has been exposed to Shiitake mushroom enzymes. This powerful immune booster stimulates the activity of T and B cells, particularly the NK (natural killer) cells which form our first line immune defence.

Immusan is an herbal extract mix made from 15 medicinal plants. In controlled conditions, it inhibits cancer cell division, increasing the NK cells. It is taken by many cancer patients as a complementary phytotherapy (use of plants/plant extracts for medicinal purposes). Sometimes Dr. Pfeifer adds TMAZ zeolite, a powdered mineral supplement that boosts immune function, to assist patients that are not responding well to his treatment. This therapy is relatively new and needs time to work. Professor Pfeifer works alongside conventional treatment.

Professor Pfeifer, a Swiss oncologist, is Director of Clinical Research at Aeskulap Clinic in Switzerland. Around 10 years ago he started investigating plant-based medicines, phytotherapy and their effects. Pfeifer and his colleague Ulrich Kratzer have published clinical findings on their Prostate Protocol findings using Prostasol.